Table 3.
Summary of previous studies on etoposide/cisplatin- or irinotecan/cisplatin-based concurrent chemoradiotherapy for limited-disease small-cell lung cancer
| Author | Phase | No. of patients | Regimen | Radiation dose | RR (%) | PFS (m), P-value | OS (m), P-value | Grade 3/4 toxicity (%) |
|---|---|---|---|---|---|---|---|---|
| Faivre-Finn [4] (2017) | III | 247 | EP-CCRT BID vs. QD | 45 Gy vs. 66 Gy | 15.4 vs. 13.4; HR = 1.12; p = 0. 26 | 30 vs. 25; HR = 1.18, p = 0·14; 2 year SR (56% vs. 51%) | Neutropenia (74% vs. 65%) Esophagitis (19% vs. 19%) Radiation pneumonitis (3% vs. 2%) | |
| Kubota [12] (2014) | III | 281 | EP-CCRT BID followed by IP vs. EP | 45 Gy | 12 vs. 13.2; HR 1.10; p = 0.74 | 33.6 vs. 38.4; HR = 1·09, p = 0·70; 5-year SR (33.7% vs. 35.8%) | Neutropenia (95% vs. 78%) Anemia (35% vs. 50%) Diarrhea (2% vs. 1%) | |
| Fukuda [11] (2012) | II | 34 | IP-CCRT | 50 Gy | 100 | 14.3 | 44.5; 2- and 5-year SR (66.7, 46.1%) | Neutropenia 38%; Pneumonitis 6% Diarrhea 3%; Esophagitis 0% |
| Naidu [10] (2014) | II | 36 | IP-CCRT BID | 45–54 Gy | 67 | 19; 1-, 2-, 3-year SR (60, 44, 30%) | Symptomatic pneumonitis 0% Symptomatic esophagitis 13% | |
| Saito [14] (2006) | II | 51 | EP-CCRT BID followed by IP | 45 Gy | 88 | 11.8 | 23; 2- and 3-year SR (49, 29.7%) | Neutropenia 88%; Infection 33% Electrolyte imbalance 20% Diarrhea 14% |
| Jeong [20] (2006) | II | 20 | IP-CCRT | 50.4 Gy | 85 | 12 | 20; 1- and 2-year SR (85, 35%) | Neutropenia 60%; Anemia (20%) Nausea/vomit(55%); Diarrhea (35%) |
| Hong [13] (2011) | II | 19 | IP-CCRT QD | 54 Gy | 89.5 | 7.6 | 12.4; 2-year SR (75.0%) | Radiation-induced pneumonitis 53% Neutropenia 32% |
| Sohn [8] (2007) | II | 33 | IP-CCRT BID | 45–54 Gy | 87.9 | 14.4 | 26.1; 2-year SR (54.9%) | Neutropenia 81.8%; Diarrhea 21.2% Radiation pneumonitis 9.1% |
| Han [15] (2005) | II | 33 | IP followed by EP-CCRT BID | 45 Gy | 97 | 12.9 | 25; 1- and 2-year SR (85.7, 53.9%) | Neutropenia (68% + 100%)a, Febrile neutropenia (20% + 60%)b |
RR, response rate; PFS, progression-free survival; OS, overall survival; EP, etoposide/platinum; IP, irinotecan/platinum; CCRT, concurrent chemoradiotherapy; BID, bis in die (twice a day); QD, quaque die (once a day); HR, hazard ratio; SR, survival rate
aGrade 3 or 4 neutropenia occurred during induction chemotherapy in 68% patients and during CCRT in 100% patients
bGrade 3 or 4 febrile neutropenia occurred during induction chemotherapy in 20% patients and during CCRT in 60% patients